Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva
NCT07559513Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2027
- Primary completion
- Jul 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP), sponsored by Regeneron Pharmaceuticals. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT07559513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559513.